Trial Profile
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Cancer metastases; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2022 Planned End Date changed from 31 May 2024 to 27 Sep 2024.
- 10 Nov 2022 Planned primary completion date changed from 31 May 2024 to 27 Sep 2024.
- 03 Nov 2020 Planned End Date changed from 27 Sep 2020 to 31 May 2024.